LES LABORATOIRES SERVIER · SERVIER ARDRIX EUTHERAPIE BIOPHARMA

Ivosidenib forms and pharmaceutical compositions

N° AU2025203835A1

Polygenic Risk Scores For Predicting Disease Complications And/Or Response To Therapy

N° AU2025200953A1

ANTI-FLT3 ANTIBODIES AND COMPOSITIONS

N° US2025179195A1

PROCESS FOR THE PREPARATION OF VORASIDENIB

N° US2025257050A1

PROCESS FOR THE PREPARATION OF VORASIDENIB

N° WO2025168757A1

NEW AMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS SOS1 INHIBITORS

N° WO2025163050A1

Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells

N° IL318639A

NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS

N° MX2025000310A

New spirocyclohexane derivatives, pharmaceutical compositions containing them and their uses as anti-apoptotic inhibitors

N° IL317950A

Conjugados de anticuerpo-fármaco de compuestos antineoplásicos y métodos de uso de los mismos

N° CO2024017273A2

Methods and compositions for dosing of allogeneic chimeric antigen receptor T cells

N° AU2024278176A1

Ivosidenib for use in a combination therapy of glioma

N° IL317258A

NOVEL SALT OF BCL-2 INHIBITOR, RELATED CRYSTALLINE FORM, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

N° JP2025028968A

ANTI-CD7 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF

N° WO2025111431A1

ANTI-CD74 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF

N° WO2025111450A1

METHODS AND COMPOSITIONS FOR DOSING OF ALLOGENEIC CHIMERIC ANTIGEN RECEPTOR T CELLS

N° US2025084149A1

ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF

N° MX2024014345A

Conjugados de anticuerpo-fármaco de compuestos antineoplásicos y usos de los mismos.

N° CL2024003536A1

CONJUGADOS DE ANTICUERPO-FÁRMACO DE COMPUESTOS ANTINEOPLÁSICOS Y MÉTODOS DE USO DE LOS MISMOS

N° DOP2024000245A

Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof

N° IL317103A

Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof

N° IL317102A

Antibody-drug conjugates of antineoplastic compounds and methods of use thereof

N° IL317101A

Methods of treating brain tumors using combination therapy

N° AU2024220102A1

CRYSTALLINE FORMS OF A MCL-1 INHIBITOR, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

N° US2025011337A1

Ivosidenib forms and pharmaceutical compositions

N° IL315423A

HYDROGEN SULFATE SALT OF A BCL-2 INHIBITOR, RELATED CRYSTALLINE FORM, METHOD FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

N° US2024417390A1

Oligonucleotides for modulating KCNT1 expression

N° TW202515583A

OLIGONUCLEOTIDES FOR MODULATING KCNT1 EXPRESSION

N° WO2025036916A1

5-[7-(3,4-dihydro-1h-isoquinoline-2-carbonyl)-1,2,3,4 tetrahydroisoquinolin-6-y l]-1h-pyrrole-3-carboxamide derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents

N° IL314917A

IVOSIDENIB FORMS AND PHARMACEUTICAL COMPOSITIONS

N° JP2024150784A

CRYSTALLINE AND SALT FORMS OF ORGANIC COMPOUND AND PHARMACEUTICAL COMPOSITIONS THEREOF

N° JP2024161431A

HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER

N° US2025214988A1

COCRYSTAL OF AN IDH1 INHIBITOR, PROCESS OF PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF TREATMENT INVOLVING THE SAME

N° US2025041283A1

COCRYSTAL OF AN IDH1 INHIBITOR, PROCESS OF PREPARATION THEREOF, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF TREATMENT INVOLVING THE SAME

N° WO2025027075A1

Cocrystal of an IDH1 inhibitor, process of preparation thereof, pharmaceutical compositions thereof, and methods of treatment involving the same

N° TW202508576A

SALTS, COCRYSTALS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF TREATMENT INVOLVING THE SAME

N° US2025034109A1

SALTS, COCRYSTALS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF TREATMENT INVOLVING THE SAME

N° WO2025021856A1

Salts, cocrystals, pharmaceutical compositions thereof, and methods of treatment involving the same

N° TW202519516A

Anticuerpos anti-cd73.

N° CL2024002093A1

COMBINATION THERAPY FOR TREATING MALIGNANCIES

N° WO2025006388A2

TABLET COMPOSITIONS

N° US2024335450A1

METHODS OF TREATING BRAIN TUMORS USING COMBINATION THERAPY

N° US2024325401A1

COCRYSTALS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF TREATMENT INVOLVING THE SAME

N° JP2024113028A

METHOD FOR THE BIOSYNTHESIS OF DIOSMIN AND/OR HESPERIDIN IN A MICROORGANISM

N° US2024409976A1

ANTI-MET ANTIBODIES, ANTIBODY-DRUG CONJUGATES, COMPOSITIONS AND USES THEREOF

N° WO2024240634A1

Anti-MET antibodies, antibody-drug conjugates, compositions and uses thereof

N° TW202500584A

ANTICUERPOS ANTI-MET, ADC, COMPOSICIONES Y USOS DE LOS MISMOS

N° AR132710A1

Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same

N° AU2024203186A1

ANTI-NKG2A ANTIBODIES AND COMPOSITIONS

N° US2024294638A1

NOVEL TRIMETAZIDINE SOLID PHASES

N° WO2024218267A2

NUEVAS FASES SÓLIDAS DE TRIMETAZIDINA

N° AR132479A1

Terapia del cáncer dirigida a nkg2a

N° CO2024004788A2

Novel trimetazidine salts

N° IL311916A

Terapia del cáncer dirigida a nkg2a

N° CL2024000972A1

Cancer therapy targeting nkg2a

N° IL311736A

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

N° JP2024057088A

PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

N° US2024245699A1

COMBINATION THERAPIES TARGETING PD-1, TIM-3, AND LAG-3

N° US2024270848A1

MÉTODO DE PREPARACIÓN DE UN COMPUESTO INHIBIDOR DE MUTANTES DE IDH1 Y/O IDH2

N° AR131555A2

Procedimiento para la preparación de diosmina y de fracción flavonoica

N° CO2023018582A2

AZA-HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER

N° JP2024015340A

Anticuerpos y composiciones anti-nkg2a

N° CL2023003562A1

Anticuerpos anti-nkg2a y composiciones

N° CO2023015982A2

Anti-nkg2a antibodies and compositions

N° IL308695A

COCRYSTALS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF TREATMENT INVOLVING SAME

N° US2024343705A1

METHODS AND COMPOSITIONS FOR DOSING OF ALLOGENEIC CHIMERIC ANTIGEN RECEPTOR T CELLS

N° JP2024014911A

COMBINATION THERAPIES TARGETING PD-1, TIM-3, AND LAG-3

N° JP2024023222A

ΠΑΡΑΓΩΓΑ ΛΑΚΤΑΜΗΣ ΧΡΗΣΙΜΑ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΜΕΤΑΛΛΑΓΜΕΝΗΣ IDH1

N° CY2023023I1

PHARMACEUTICAL COMPOSITIONS OF THERAPEUTICALLY ACTIVE COMPOUNDS

N° JP2024001219A

Ivosidenib or a pharmaceutically acceptable salt, tautomer, isotopologue or hydrate thereof

N° NO2023038I1

Methods and compositions for dosing of allogeneic chimeric antigen receptor T cells

N° US2024041930A1

LACTAM DERIVATES USEFUL AS INHIBITORS OF MUTANT IDH1

N° HUS2300035I1

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

N° US2024335448A1

Ivosidenib of een farmaceutisch aanvaardbaar zout, tautomeer, isotopoloog of hydraat daarvan

N° NL301243I2

New process for the synthesis of 5-{5-chloro-2-[(3s)-3-[(morpholin-4-yl)methyl]-3,4-dihydroisoquinoline-2(1h)- carbonyl]phenyl}-1,2-dimethyl-1h-pyrrole-3-carboxylic acid derivatives and its application for the production of pharmaceutical compounds

N° IL306011A

Macrocyclic lrrk2 kinase inhibitors

N° IL305877A

DERIVES DE LACTAMES EN TANT QU'INHIBITEURS D'IDH1 MUTANTS

N° FR23C1031I1

Oligonucleótidos antisentido para inhibir la expresión de la alfa-sinucleína

N° CL2023002644A1

Antisense oligonucleotides for inhibiting alpha-synuclein expression

N° IL305668A

PHARMACEUTICAL COMPOSITIONS OF THERAPEUTICALLY ACTIVE COMPOUNDS

N° ZA202308495B

PHARMACEUTICAL COMPOSITIONS OF THERAPEUTICALLY ACTIVE COMPOUNDS

N° ZA202308496B

Therapeutically active compounds and their methods of use

N° IL305019A

Selective bcl-xl protac compounds and methods of use

N° IL304891A

신규 스피로시클로헥산 유도체, 그를 함유하는 제약 조성물 및 항아폽토시스 억제제로서의 그의 용도

N° KR20250048158A

NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS

N° WO2024008941A1

NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS

N° EP4551566A1

NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS

N° AU2023302094A1

Novel spirocyclohexane derivatives, pharmaceutical compositions containing them and their use as anti-apoptosis inhibitors

N° CN119816491A

NOUVEAUX DÉRIVÉS DE SPIROCYCLOHEXANE, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET LEURS UTILISATIONS COMME INHIBITEURS ANTI-APOPTOTIQUES

N° MA71381A

Spirocyclohexane derivatives, pharmaceutical compositions containing them and their uses as anti-apoptotic inhibitors

N° IL304247A

ΚΑΙΝΟΤΟΜΟΣ ΧΙΜΑΙΡΙΚΗ ΠΡΩΤΕΪΝΗ ΕΙΔΙΚΗ ΓΙΑ ΤΙΣ CD137 ΚΑΙ PD-L1

N° CY1126148T1

BICYCLIC INHIBITOR OF MAT2A, AND METHOD OF USE THEREOF FOR TREATING CANCER

N° JP2023101762A

METHODS OF USING TRISUBSTITUTED BENZOTRIAZOLE DERIVATIVES

N° JP2023109974A

Mcl-1 inhibitor antibody-drug conjugates and methods of use

N° IL303079A

EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF

N° EP4525925A1

MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF

N° EP4525926A1

EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF

N° AU2023271885A1

EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF

N° WO2023225320A1

MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF

N° WO2023225336A1

Antibody-drug conjugates of antineoplastic compounds and methods of use thereof

N° TW202408588A